linjc16/ctgov huggingface dataset:
Stent For Life Observatory

Study Overview
=================
Brief Summary
-----------------
Observatory multicenter, prospective, to support the acute phase of acute coronary syndromes with ST segment elevation ST (myocardial infarction).

Official Title
-----------------
Stent For Life Observatory

Conditions
-----------------
Acute Coronary Syndrome, Myocardial Infarction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any patient with a myocardial infarction less than 48 hours during the November 2010 is eligible and should be considered for inclusion in the study. Every patient who agreed to participate in the study Exclusion Criteria: Patients with myocardial infarction after a coronary revascularization, or after cardiac surgery or extra heartbeat. Patient denying that his personal data are subject to treatment automated

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Acute coronary Syndrome<br>Patients affected are patients with acute coronary syndrome with ST segment elevation ST (myocardial infarction) in 48 hospitalized in one of the centers (emergency, ambulance, intensive care unit, cardiac catheterization lab). | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Phase IV Study of Chronic Infusional Epoprostenol for Severe Primary Pulmonary Hypertension

Study Overview
=================
Brief Summary
-----------------
OBJECTIVES: I. Provide epoprostenol (Flolan, prostaglandin I2) by chronic infusion to patients with severe primary pulmonary hypertension for whom no alternative therapy is available. II. Obtain additional safety information on continuous infusion epoprostenol. III. Obtain additional information on economic resource health consumption.

Detailed Description
-----------------
PROTOCOL OUTLINE: Patients are treated with a chronic continuous infusion of epoprostenol. The highest tolerated infusion rate is determined for each patient by gradually increasing the rate until the target dose is reached or the patient experiences at least 1 dose-limiting effect. Patients are subsequently treated with a chronic continuous infusion, beginning at a rate below the highest tolerated rate. Attempts are made to increase the dose to the highest tolerated rate over the first 72 hours.

Conditions
-----------------
Hypertension, Pulmonary

Intervention / Treatment
-----------------
* Drug: epoprostenol


Participation Criteria
=================
Eligibility Criteria
-----------------
PROTOCOL ENTRY CRITERIA: Severe primary pulmonary hypertension Able to prepare and self-administer medication

Ages Eligible for Study
-----------------
Minimum Age: 0 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: epoprostenol|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cardiovascular and respiratory diseases, hypertensive disorder, primary pulmonary hypertension, rare disease
Trial to Assess Best Methods for Engaging Academic Physicians in Grateful Patient Philanthropy

Study Overview
=================
Brief Summary
-----------------
This study attempted to identify the best method for educating and engaging academic physicians in grateful patient philanthropy.

Detailed Description
-----------------
In this small trial assessing the impact of educational methodologies, we are looking to determine which of the following 3 approaches will be most successful in engaging academic physicians in grateful patient philanthropy; email advice didactic session led by experts one-on-one coaching by development professionals

Official Title
-----------------
Trial to Assess Best Methods for Engaging Academic Physicians in Grateful Patient Philanthropy

Conditions
-----------------
Physician's Role

Intervention / Treatment
-----------------
* Behavioral: education


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: academic physicians Exclusion Criteria: having secured grateful patient philanthropy in past
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: emails, book<br> | Behavioral: education<br>* teaching<br>|
| Active Comparator: didactic teaching from experts<br> | Behavioral: education<br>* teaching<br>|
| Experimental: personal coaching by development profs<br> | Behavioral: education<br>* teaching<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| qualified referrals to development office | Individuals able to make a donation of $25,000 based on criteria established by Hopkins Office of Development. | 6 month follow-up period |
Medium and Long Term Outcome of Total Hip Arthroplasty Using Accolade TMZF Femoral Stem

Study Overview
=================
Brief Summary
-----------------
This is a retrospective/prospective study evaluating the clinical and radiographic outcome of total hip arthroplasty (THA) performed using Accolade femoral stem in a consecutive group of patients. All patients eligible for inclusion will be identified. The investigators hypothesize that the outcome of THA performed using Accolade femoral stem is equal or superior to historical survivorship of THA using other types of collarless, proximally coated, tapered stems.

Official Title
-----------------
Medium and Long Term Outcome of Total Hip Arthroplasty Using Accolade TMZF Femoral Stem

Conditions
-----------------
Osteoarthritis of the Hip

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients undergoing THA prior to 1/1/2003 using Accolade femoral stem. Patients with hip fracture undergoing THA will also be included. Patients willing and able to comply with follow-up requirements and self-evaluations.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The outcome of THA performed using Accolade femoral stem is equal or superior to historical survivorship of THA using other types of collarless, proximally coated, tapered stem |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proximally coated tapered stems can be used for patients with various bone types, bone morphology, and underlying diagnosis |  |  |
The Evolutionary Model of Mild-to-moderate Myopia in China

Study Overview
=================
Brief Summary
-----------------
Myopia has emerged as a major health issue in east Asia, because of its increasingly high prevalence in the past few decades (now 80-90% in school-leavers), and because of the sight-threatening pathologies associated with high myopia, which now aff ects 10-20% of those completing secondary schooling in this part of the world. Similar, but less marked, changes are occurring in other parts of the world. The higher prevalence of myopia in east Asian cities seems to be associated with increasing educational pressures, combined with life-style changes, which have reduced the time children spend outside.

Detailed Description
-----------------
Myopia has emerged as a major health issue in east Asia, because of its increasingly high prevalence in the past few decades (now 80-90% in school-leavers), and because of the sight-threatening pathologies associated with high myopia, which now aff ects 10-20% of those completing secondary schooling in this part of the world. Similar, but less marked, changes are occurring in other parts of the world. The higher prevalence of myopia in east Asian cities seems to be associated with increasing educational pressures, combined with life-style changes, which have reduced the time children spend outside. In this trial, the investigators aim to study the evolutionary model of myopia in China, which could provide new insight into the social development and human adaptation.

Official Title
-----------------
The Evolutionary Model of Mild-to-moderate Myopia in China

Conditions
-----------------
Refractive Error

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients complete the examination of Refractive error from 2005 to 2015 year. Exclusion Criteria: Patients could not complete the examination of Refractive error
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Refractive error of both eyes measured by autorefractor and subjective measuring |  | Baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Evolutionary Model
Effect of Gemigliptin or Acarbose on Endothelial Function in Type 2 DM Patients

Study Overview
=================
Brief Summary
-----------------
This is a phase 4, single center, randomized, open-labeled study. The primary objective of the study is to compare effect of gemigliptin and acarbose on endothelial function. Subjects are randomized to gemigliptin or acarbose group and maintained intial treatment for 4 weeks.

Official Title
-----------------
Effect of Gemigliptin or Acarbose on Endothelial Function in Type 2 DM Patients (GetUp Trial)

Conditions
-----------------
Endothelial Function, Type 2 Diabetes, Gemigliptin, Acarbose

Intervention / Treatment
-----------------
* Drug: Gemigliptin
* Drug: Acarbose


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age: 20-80yrs patients with type 2 diabetes (duration of diabetes >=3 months) HbA1c :>7.0 and <=9.0% on metformin monotherapy no changes on medications during recent 3 months. Exclusion Criteria: patients with type 1 diabetes history of medications including α-glucosidase inhibitor, glinide, GLP-1 analogue, other DPP-4 Inhibitors, or insulin during recent 3 months. history of acute diabetic complication, acute coronary events, or coronary bypass surgery/interventions during recent 6 months. patients with congestive heart failure (NYHA II IV) or clinically significant ventricular arrhythmia serum ALT or AST> 2.5 x upper normal range serum direct bilirubin > 1.3 x upper normal range serum creatinine > (men) 1.5 mg/dL, (women)>1.4 mg/dL smoker pregnant women, or breast-feeding women medication with acetylsalicylic acid or vitamin K antagonist

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: gemigliptin<br>gemigliptin for 4 weeks | Drug: Gemigliptin<br>* Gemigliptin for 4 weeks<br>|
| Active Comparator: acarbose<br>acarbose for 4 weeks | Drug: Acarbose<br>* Acarbose for 4 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| endothelial function (reactive hyperemic index) |  | 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fasting plasma glucose |  | 4 weeks | 
| Postprandial 2hour glucose |  | 4 weeks | 
| Glycated albumin |  | 4 weeks |
Anesthesia for Catheter Aortic Valve ImplantATIOn Registry

Study Overview
=================
Brief Summary
-----------------
In modern cardiac surgery and cardiology Transcatheter Aortic Valve Implantation (TAVI) is an emerging procedure for high-risk patients that are assumed to be otherwise inoperable. The investigators want to evaluate the specific intraoperative anesthesiologic characteristics cardiac anesthesiologists have to face during these procedures.

Official Title
-----------------
Anesthesia for Catheter Aortic Valve ImplantATIOn Registry

Conditions
-----------------
Heart Failure, Excessive Amount of Blood / Fluid Transfusion, Intraoperative Cardiac Arrest During Cardiac Surgery, Critical Incident, Anesthesia, Failed Conscious Sedation During Procedure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Patients undergoing transcatheter aortic valve implantation (TAVI) Exclusion Criteria: - Refusal by patient

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Perioperative Care | major critical adverse events | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Up to 10 years | all-cause mortality | 10 Years |
Measuring Subjective Visual Vertical (SVV) Using a Smartphone Application

Study Overview
=================
Brief Summary
-----------------
A comparison between two methods evaluating SVV: Bucket Test and A smartphone-based test.

Official Title
-----------------
Measuring Subjective Visual Vertical (SVV) Using a Smartphone Application

Conditions
-----------------
Subjective Visual Vertical

Intervention / Treatment
-----------------
* Diagnostic Test: Bucket test and Smartphone-based evaluation of SVV


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Vestibular Disorder Exclusion Criteria: Chronic ear disease, Neurological disorder, s/p Ear surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Vertigo<br>Participants with vestibular disorder | Diagnostic Test: Bucket test and Smartphone-based evaluation of SVV<br>* Bucket test and Smartphone-based evaluation of SVV<br>|
| Active Comparator: Control<br>Participants without vestibular disorder | Diagnostic Test: Bucket test and Smartphone-based evaluation of SVV<br>* Bucket test and Smartphone-based evaluation of SVV<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Results of Bucket test Smartphone-based evaluation of SVV |  | 5 minutes | 
| Results of Smartphone-based evaluation of SVV |  | 5 minutes |
Intermittent Fasting in Refractory Epilepsy

Study Overview
=================
Brief Summary
-----------------
This is an open trial of intermittent fasting in a group of patients with refractory seizures. Patients will continue on the diet for 6 months to assess the impact of the diet on seizure frequency.

Detailed Description
-----------------
A proportion of people with epilepsy continue to have seizures despite all conventional treatment options. The classical ketogenic diet and its variants have been shown to help some of these people. However, these diets require significant medical and dietician supervision,and is frequently not well tolerated. There is a need to develop other diet therapy that is easier to administer and more acceptable to the patient. This trial undertaken in adult overweight UCLH outpatients examines the effect of an intermittent fasting diet on seizures. Subjects may consume their normal diet for 5 days a week. On 2 days in a week, they consume only 25% of their daily calorie requirement. Subjects will continue on the diet for 6 months. Intermittent fasting has been shown in animal studies to activate a number of signalling pathways which are thought to reduce seizure thresholds. Has intermittent fasting in humans might be expected to reduce seizures.

Official Title
-----------------
A Single Centre Open Six Months Study of Intermittent Fasting for the Treatment of People With Refractory Epilepsy.

Conditions
-----------------
Epilepsy

Intervention / Treatment
-----------------
* Other: Intermittent fasting


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Experiencing at least 2 seizures per month .BMI of 25 or over Exclusion Criteria: Current/previous eating disorder Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intermittent fasting<br>Patients consume their normal diet for 5 days in the week. On 2 days they only consume 500 Cals if female and 600 Cals if male. | Other: Intermittent fasting<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Daily total number of seizures |  | up to 6 months |
Ultrasound (US)-Doppler for the Diagnosis of Asymptomatic Deep Vein Thrombosis (DVT) in Gynecologic Cancer Patients

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to determine the prevalence of asymptomatic lower extremity DVT detected by Doppler ultrasound in a selected group of patients suffering from gynecological malignancies.

Detailed Description
-----------------
The association between malignancy and venous thromboembolism (VTE) is well known. It has been shown that there is a high prevalence of VTE in gynecological malignancies. Early detection of VTE can identify patients who may benefit from anticoagulant therapy and prevent morbidity and mortality. NO clear guidelines are available for anticoagulant prophylaxis in a selected group of ambulatory gynecological cancer patients. It has been shown, in other selected groups of patients that Ultrasound Doppler can be used in order to diagnose asymptomatic DVT (deep vein thrombosis).

Official Title
-----------------
US-Doppler for the Diagnosis of Asymptomatic DVT in Gynecologic Cancer Patients

Conditions
-----------------
Deep Vein Thrombosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Gynecological cancer patients Ambulatory performance status of 0-2 Prior to, or during, chemotherapy and/or radiation Exclusion Criteria: Before or near surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Deep vein thrombosis, Gynecological cancer
Micro Ribonucleic Acid (RNA) as Cholinergic Tone and Inflammatory Regulator in Inflammatory Bowel Disease

Study Overview
=================
Brief Summary
-----------------
There is a reciprocal relationship between the central nervous system and the immune system. Stimulation of the vagus nerve results in secretion of acetylcholine (Ach) which decreases secretion of pro-inflammatory cytokines. Acetylcholine esterase is an enzyme that neutralizes Ach and thus, involves in regulation of Ach levels, and in the cholinergic tone and inflammatory state. MicroRNAs (miRs) are evolutionarily conserved, RNAs that regulate gene expression. The investigators hypothesized that miRs controlling systemic communication processes function in one tissue in response to signals (i.e. neuronal, hormonal or others) from another. Specifically, the investigators hypothesized that miRs control the inflammatory response in inflammatory bowel diseases through regulation of expression of messenger RNA of AchE.

Conditions
-----------------
Inflammatory Bowel Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Inflammatory bowel disease patients under going colonoscopy Exclusion Criteria: Debilitated patients who need an apotropsy Age < 18 or age > 75 Pregnant women Evidence of previous or current cancer Inflammatory disease other than IBD

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| IBD<br>Inflammatory bowel disease patients | |
| Control<br>Average risk patients undergoing screening colonoscopy | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Elevated expression of specific micro RNAs that regulate the expression of the enzyme Acetylcholine esterase in inflammatory bowel disease patients compared to healthy controls. |  | one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| A statistically significant relation between micro RNA expression and disease activity and inflammatory indices |  | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
inflammatory bowel disease, micro RNA, cholinergic tone, inflammation